



## ANTIPHOSPHOLIPID SYNDROME

RMA ID Number	Reference List for RMA403-1 as at August 2016
---------------	---

77998	Al Abdulhai SA, El-Ali MW, El-Dahshan Mel-S (2015). Bleeding and thrombosis in a patient with primary antiphospholipid syndrome using norethisterone: a case report. <i>J Med Case Rep</i> , 9: 87.
77878	Asherson RA, Cervera R, de Groot PG, et al (2003). Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. <i>Lupus</i> , 12(7): 530-4.
77879	Asherson RA, Cervera R (2003). Antiphospholipid antibodies and infections. <i>Ann Rheum Dis</i> , 62(5): 388-93.
77883	Asherson RA, Cervera R, Piette JC, et al (2001). Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. <i>Medicine (Baltimore)</i> , 80(6): 355-77.
77863	Bryant J, Forty T, Shelton J (2014). Lupus coagulopathy post-tasing: A case study. <i>West Virginia Medical Journal</i> , 110(6): 20-2.
77910	Caldas CA, da Mota LM, de Carvalho JF (2011). [Comment] Obesity in primary antiphospholipid syndrome is associated with worse outcome. <i>Joint Bone Spine</i> , 78(3): 324-5.
77882	Carvalho JF (2008). [Comment] Some concerns about the Sydney criteria for antiphospholipid syndrome. <i>Lupus</i> , 17(8): 770.
77870	Catoggio C, Alvarez-Uria A, Fernandez PL, et al (2012). Catastrophic antiphospholipid syndrome triggered by fulminant disseminated herpes simplex infection in a patient with systemic lupus erythematosus. <i>Lupus</i> , 21(12): 1359-61.
77884	Cervera R (2016). The catastrophic antiphospholipid syndrome. . Retrieved 30 March 2016, from <a href="https://ontocrf.grupocostaisa.com/es/web/caps/contents">https://ontocrf.grupocostaisa.com/es/web/caps/contents</a>
77912	Cervera R, Bucciarelli S, Plasini MA, et al (2009). Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the "CAPS Registry". <i>J Autoimmun</i> , 32(3-4): 240-5.
77885	Cervera R, Font J, Gomez-Puerta JA, et al (2005). Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. <i>Ann Rheum Dis</i> , 64: 1205-9.
77866	Cervera R, Rodriguez-Pinto I, Espinosa G, et al (2014). Catastrophic antiphospholipid syndrome: task force report summary. <i>Lupus</i> , 23(12): 1283-5.
77877	Chighizola CB, Raschi E, Borghi MO, et al (2015). Update on the pathogenesis and treatment of the antiphospholipid syndrome. <i>Curr Opin Rheumatol</i> , 27(5): 476-82.
78002	Chopra N, Koren S, Greer WL, et al (2002). Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. <i>J Rheumatol</i> , 29(8): 1683-8.
77871	Cruz-Tapias P, Blank M, Anaya JM, et al (2012). Infections and vaccines in the etiology of antiphospholipid syndrome. <i>Curr Opin Rheumatol</i> , 24(4): 389-93.

77999	da Silva FF, Levy RA, de Carvalho JF (2014). Cardiovascular risk factors in the antiphospholipid syndrome. <i>J Immunol Res</i> , 2014: 621270.
78027	Danowski A, de Azevedo MN, de Souza Papi JA, et al (2009). Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. <i>J Rheumatol</i> , 36(6): 1195-9.
78007	Davies R, Galloway JB, Watson KD, et al (2011). Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. <i>Ann Rheum Dis</i> , 70(10): 1831-4.
77865	de Meis E, Bradao BC, Capella FC, et al (2014). Catastrophic antiphospholipid syndrome in cancer patients: an interaction of clotting, autoimmunity and tumor growth? <i>IMA J</i> , 16(9): 544-7.
77967	de Souza AW, Silva NP, de Carvalho JF, et al (2007). Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. <i>Lupus</i> , 16(10): 782-7.
77867	Durkin ML, Marchese D, Robinson MD, et al (2013). Catastrophic antiphospholipid syndrome (CAPS) induced by influenza A virus subtype H1N1. <i>BMJ Case Rep</i> , 2013: pii: bcr2013200474.
77968	Eklund KK, Peltomaa R, Leirisalo-Repo M (2003). [Comment] Occurrence of pulmonary thromboembolism during infliximab therapy. <i>Clin Exp Rheumatol</i> , 21(5): 679.
77888	Erkan D, Asherson RA, Espinosa G, et al (2003). Long term outcome of catastrophic antiphospholipid syndrome survivors. <i>Ann Rheum Dis</i> , 62: 530-3.
77886	Erkan D, Schur PH (2015). Diagnosis of the antiphospholipid syndrome. . Retrieved 30 March 2016, from <a href="http://www.uptodate.com/contents/diagnosis-of-the-antiphospholipid-syndrome?topic">http://www.uptodate.com/contents/diagnosis-of-the-antiphospholipid-syndrome?topic</a>
78001	Erkan D, Yazici Y, Peterson MG, et al (2002). A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. <i>Rheumatology</i> , 41(8): 924-9.
77887	Erkan D, Zuily S (2016). Clinical manifestations of the antiphospholipid syndrome. . Retrieved 30 March 2016, from <a href="http://www.uptodate.com/contents/clinical-manifestations-of-the-antiphospholipid-syndrome?source=search_result&amp;search=clinical+manifestations+of+the+antiphospholipid+sy&amp;selectedTitle=1%7E150">http://www.uptodate.com/contents/clinical-manifestations-of-the-antiphospholipid-syndrome?source=search_result&amp;search=clinical+manifestations+of+the+antiphospholipid+sy&amp;selectedTitle=1%7E150</a>
77966	Espinosa G, Cervera R (2010). Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. <i>Natl Rev Rheumatol</i> , 6(5): 296-300.
78011	Ferraro-Peyret C, Coury F, Tebib JG, et al (2004). Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. <i>Arthritis Res Ther</i> , 6(6): R535-43.
77868	Gary T, Belaj K, Bruckenberger R, et al (2013). Primary antiphospholipid antibody syndrome-one further aspect of thrombophilia in overweight and obese patients with venous thromboembolism. <i>Obesity</i> , 21(9): E463-6.
77869	Giannakopoulos B, Krilis SA (2013). The pathogenesis of the antiphospholipid syndrome. <i>N Eng J Med</i> , 368(11): 1033-44.
77965	Gigante A, Gasperini ML, Cianci R, et al (2009). Antiphospholipid antibodies and renal involvement. <i>Am J Nephrol</i> , 30(5): 405-12.
77957	Girolami A, Zanon E, Zanardi S, et al (1996). Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. <i>Blood Coagul Fibrinolysis</i> , 7(4): 497-501.
78000	Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C, et al (2004). Prospective analysis of 404 individuals. <i>J Rheumatol</i> , 31(8): 1560-7.

77880	Gomez-Puerta JA, Cervera R (2014). Diagnosis and classification of the antiphospholipid syndrome. <i>J Autoimmun</i> , 48-49: 20-5.
78016	Hoayek JG, Mousa HN, Rehman HA, et al (2016). Catastrophic antiphospholipid syndrome in pregnancy, a diagnosis that should not be missed. <i>J Matern Fetal Neonatal Med</i> , : Epub ahead of print.
78010	Jonsdottir T, Forslid J, van Vollenhoven A, et al (2004). Treatment with tumour necrosis factor $\alpha$ antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. <i>Ann Rheum Dis</i> , 63(9): 1075-8.
78006	Kim SC, Solomon DH, Liu J, et al (2015). Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. <i>Am J Med</i> , 128(5): 539.e7-17.
77864	Lazzaroni MG, Taglietti M, Tincani A (2014). Malignancies: A possible "first hit" in the development of catastrophic antiphospholipid syndrome? <i>IMAJ</i> , 16(9): 583-4.
77872	Lee CH, Chuah SK, Pei SN, et al (2011). Acute Q fever presenting as antiphospholipid syndrome, pneumonia, and acalculous cholecystitis and masquerading as <i>Mycoplasma pneumoniae</i> and hepatitis C viral infections. <i>Jpn J Infect Dis</i> , 64(6): 525-7.
78005	Makol A, Grover M, Guggenheim C, et al (2010). Etanercept and venous thromboembolism: a case series. <i>J Med Case Rep</i> , 4: 12.
77874	Martin E, Winn R, Nugent K (2011). Catastrophic antiphospholipid syndrome in a community-acquired methicillin-resistant <i>Staphylococcus aureus</i> infection: A review of pathogenesis with a case for molecular mimicry. <i>Autoimmun Rev</i> , 10(4): 181-8.
77958	Matyja-Bednarczyk A, Swadzba J, Iwaniec T, et al (2014). Risk factors for arterial thrombosis in antiphospholipid syndrome. <i>Thromb Res</i> , 133(2): 173-6.
77876	Medina G, Calleja C, Moran M, et al (2009). Catastrophic antiphospholipid syndrome in a patient with Down syndrome. <i>Lupus</i> , 18(12): 1104-7.
77862	Merashli M, Noureddine MH, Uthman I, et al (2015). Antiphospholipid syndrome: an update. <i>Eur J Clin Invest</i> , 45(6): 653-62.
77875	Meyer A, Rotman-Pikielny P, Natour A, et al (2010). Antiphospholipid syndrome following a diphtheria-tetanus vaccination: coincidence vs. causality. <i>IMAJ</i> , 12(10): 638-9.
78028	Mirzayan MJ, Schmidt RE, Witte T (2000). Prognostic parameters for flare in systemic lupus erythematosus. <i>Rheumatology</i> , 39: 1316-9.
77881	Miyakis S, Lockshin MD, Atsumi T, et al (2006). International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). <i>J Thromb Haemost</i> , 4(2): 295-306.
77889	Movva S (2015). Antiphospholipid syndrome.. Retrieved 30 March 2016, from <a href="http://emedicine.medscape.com/article/333221-overview">http://emedicine.medscape.com/article/333221-overview</a>
77962	Namazi MH, Khaheshi I, Serati AR, et al (2015). Resistant hypertension due to unilateral renal artery occlusion as the first presentation of antiphospholipid syndrome. <i>Cardiovasc Revasc Med</i> , 16(3): 190-1.
78008	Petitpain N, Gambier N, Wahl D, et al (2009). Arterial and venous thromboembolic events during anti-TNF therapy: A study of 85 spontaneous reports in the period 2000-2006. <i>Biomed Mater Eng</i> , 19(4-5): 355-64.
78003	Rodriguez-Pinto I, Soriano A, Espinosa G, et al (2014). Catastrophic antiphospholipid syndrome: an orchestra with several musicians. <i>Isr Med Assoc J</i> , 16(9): 585-6.
77960	Saraiva Sda S, Custodio IF, Mazetto Bde M, et al (2015). Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. <i>Thromb Res</i> , 136(6): 1174-8.

77890	Schur PH (2014). Pathogenesis of the antiphospholipid syndrome. . Retrieved 30 March 2016, from <a href="http://www.uptodate.com/contents/pathogenesis-of-the-antiphospholipid-syndrome?topic">http://www.uptodate.com/contents/pathogenesis-of-the-antiphospholipid-syndrome?topic</a>
77891	Schur PH, Kaplan AA (2015). Treatment of the antiphospholipid syndrome. . Retrieved 30 March 2016, from <a href="http://www.uptodate.com/contents/treatment-of-the-antiphospholipid-syndrome?topic">http://www.uptodate.com/contents/treatment-of-the-antiphospholipid-syndrome?topic</a>
77873	Tavakoli M, Roghaee S, Soheilian R, et al (2011). Antiphospholipid syndrome following toxoplasma retinochoroiditis. Ocul Immunol Inflamm, 19(5): 311-3.
78009	Ungprasert P, Srivali N, Spanuchart I, et al (2014). Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol, 33(3): 297-304.
77963	Urbanus RT, Siegerink B, Roest M, et al (2009). Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol, 8(11): 998-1005.
78004	Virupannavar S, Brandau A, Guggenheim C, et al (2014). Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome. Case Reports in Rheumatology, 2014: 801072.